Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. - sprookjes - yvandenbroek - TriplyDB

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

http://www.wikidata.org/entity/Q27851801

about

B-Raf and the inhibitors: from bench to bedside Molecular biology of lung cancer Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations Genomic diversity of colorectal cancer: Changing landscape and emerging targets Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma Cutaneous Side Effects of BRAF Inhibitors in Advanced Melanoma: Review of the Literature Renal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma New therapeutic strategies for BRAF mutant colorectal cancers Melanoma: oncogenic drivers and the immune system Molecular profiling in the treatment of colorectal cancer: focus on regorafenib Recent advances in the treatment of melanoma with BRAF and MEK inhibitors What links BRAF to the heart function? New insights from the cardiotoxicity of BRAF inhibitors in cancer treatment Molecular phenotypes of colorectal cancer and potential clinical applications Differences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese population Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma Molecular landscape of pancreatic cancer: implications for current clinical trials Emerging targeted therapies for melanoma treatment (review)Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions Melanoma brain metastases: an unmet challenge in the era of active therapy Optimal management of metastatic melanoma: current strategies and future directions Progression of cutaneous melanoma: implications for treatment The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy Dabrafenib: A New Therapy for Use in BRAF-Mutated Metastatic Melanoma Targeted therapies in development for non-small cell lung cancer Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.CIViC database BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.The Impact of Genomic Profiling for Novel Cancer Therapy--Recent Progress in Non-Small Cell Lung Cancer Melanoma Brain Metastasis: Mechanisms, Models, and Medicine Unveiling changes in the landscape of patient populations in cancer early drug development RAS and BRAF in metastatic colorectal cancer management BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy RASopathic skin eruptions during vemurafenib therapy BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications

P2860

Q21851559-260F5896-8097-403C-A069-32158B55C20C

P1310

2046b8239ae725fe005ec74b7267bea0f788aba9 b9e3cfe5fedf4483555e3846b91f17e574f03897

P248

Q21198860-1BAD43EF-EDAF-42B2-80A9-732EEE96EDD4 Q24606677-EABAC8AA-B404-4F5D-AFC0-C1AE0843B2A3 Q24632064-A31EEE88-FA13-438C-98B4-3C2729E32FF3 Q26739052-B1785B38-3DFB-4280-A672-545FADEADE17 Q26745933-864B2B2C-B40A-435D-B4A5-21D4C5C0FC54 Q26752774-3D9F0197-DC8A-42C8-BC4E-1CF34AD6DDF8 Q26764883-5C26FCF9-E721-45CB-8378-21439DCD579A Q26764899-F1BA611E-8493-4E1B-BD20-075EE4B52C75 Q26772015-A4B48B8A-09C6-49E9-B5B7-62A534618461 Q26772277-D21E3560-B500-45FA-8F9A-C364AE94E623 Q26775598-D3CE8BAD-D996-4E58-8859-1F17567A3787 Q26778296-B856A72E-B29A-4465-95A0-652AD3696139 Q26778769-A7B9B40D-D0AA-4C2F-A58C-043390A1D196 Q26782585-B134CF18-0ED8-4E5E-8A50-7883FE4AD5F9 Q26785725-4D2B039C-AEA9-494F-AEE7-64B591FF68E5 Q26786594-8F2F4CED-775A-45CA-805F-9D3C2F1F3A39 Q26800005-6245FB2E-F85C-4B22-BB25-EAA95160EC03 Q26824310-6EADEC2E-DC54-42FB-B52E-287E0FD59B91 Q26824528-B13A0A0F-07BE-4BF5-8A1A-722ABF453319 Q26829997-16CC321A-CA6C-4A49-8D61-90A00F1ACAF3 Q26863326-505A01B6-E423-4C80-A853-371DF9F0C78E Q26995622-4E6D901C-6AAF-42A5-A7E6-0E580AAA4105 Q26997338-CE445B6C-75FC-4C35-90BA-26E0F491B162 Q27001734-9888693C-5CA5-4B18-96E1-267487714B42 Q27004672-8E8A6F8C-E430-4F9A-950F-7B371883E9A2 Q27014945-284B3FF7-B992-463E-BFDA-D79E8D8FB8FD Q27022852-0640E303-F777-4F70-8006-3D9003E13C82 Q27027458-51E3C146-C6CF-43D1-AB4D-3C59E4C23DE7 Q27329810-40A35E3C-17CC-450F-9A2D-D5FA9DCA84CF Q27612411-C0D21FFF-9DF9-4FC7-8C2D-5FE315250553 Q27851843-399B59FC-6188-4510-ADB2-2C7D4DAB19C9 Q27853216-BF0EAC95-C36B-41C7-A0A9-CFE885784A0F Q27853224-0DCD8042-1294-475A-A13B-C0B4DFF60275 Q28067196-9FDEE491-81BA-4EE3-AE05-5C0FFC57D49E Q28069421-511E0B95-8EC0-4FA1-9854-12BC6B188776 Q28073826-E5FAE395-9277-46BA-96A6-77C5398F3623 Q28074175-39DFC0DE-18FD-40BC-AFF2-947C5B88FEDC Q28076667-87449C26-6633-4459-8F24-CA276619A351 Q28488013-EBC3CDEF-2CA5-4F64-BFFD-EC384BB90400 Q28543370-1EBB2707-20A0-48A9-A126-25549B969EDC

P2860

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

http://www.wikidata.org/entity/Q27851801

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@ast

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@en

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@nl

type

label

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@ast

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@en

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@nl

altLabel

Dabrafenib in patients with me ...... phase 1 dose-escalation trial

@en

prefLabel

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@ast

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@en

Dabrafenib in patients with me ...... phase 1 dose-escalation trial.

@nl

P1433

Q27851801-EC516191-3FB2-45EA-B696-BD2DD4F43844

P1476

Q27851801-16A2C30F-144F-4454-97B5-268C6CF277C5

P2093

Q27851801-2E595EB9-F6A4-446D-9EB0-6A9DAB06B395

Q27851801-5BE132BC-E876-456A-B946-B6B77B8D6E1B

Q27851801-6D560A9B-B095-43FA-BD6F-FD2FAF6AABE7

Q27851801-77C8D15C-D96C-41D7-BA36-38E713BB9817

Q27851801-830365AC-9C8B-4854-A9EC-18881D7CC6C7

Q27851801-98825174-6776-4BD7-BDC1-D61F706871ED

Q27851801-B0060A91-E5F4-41FD-BA5E-8B0E65B7C595

Q27851801-B7DDAA29-1CE4-4A40-80AF-29BFD34B081F

Q27851801-BD15FEF6-828F-4A50-AFBC-2D2E60311E54

Q27851801-C980F7B2-A2AF-4ADF-96E9-8C946BE887E7

P2860

Q27851801-11E29CBD-4BE6-45E4-AC17-D79ED065D85B

Q27851801-1EA644F8-67F5-4390-AD8B-6254F2A7F748

Q27851801-247FE4CE-6C52-4ADA-A47C-F1B8A735269B

Q27851801-32B27405-37E7-42C4-8609-38A5D3BBA4C4

Q27851801-3D543E09-7436-4A49-B102-264C6CABEB59

Q27851801-48198F21-922B-4DFD-AE47-985194E02055

Q27851801-5D76907D-68C7-42CA-A358-0708FFC564D1

Q27851801-61B33FFD-CFFD-42B9-8A34-7D4850F45AE6

Q27851801-6C3CC3B7-B651-4D00-80A6-28043361135D

Q27851801-6D5D0784-73DD-44EB-B36E-EC295DB3C6F7

P304

Q27851801-836B12D9-8631-4DDB-9CF6-EB58A980C6C9

P31

Q27851801-A3C045CD-F1B6-4B36-A2BB-9F2975F8AE00

P3181

Q27851801-5DE4452E-5326-4E16-8BB6-49062A3B6FE0

P356

Q27851801-73E178B2-744D-4334-BCB7-3CEE302DF1FE

P407

Q27851801-5C827E93-A3F0-4EF9-90DF-7BAD35DD1779

P433

Q27851801-8B5B21B1-FF45-4AA8-AF46-D6812EE98A63

P478

Q27851801-16DC4B75-59D0-4037-B42C-C3E50092B209

P50

Q27851801-52CF0C14-B41B-4833-91C7-00E6518B1190

Q27851801-68BF9C08-9297-45C8-9561-71565C21DC68

Q27851801-C883BD03-47A2-4CD1-ABE0-069970CBB0EA

P577

Q27851801-12576897-C1A2-4981-BD6F-78B593BFE7A5

P698

Q27851801-2A47AD9C-3306-41FF-8219-3366456E7761

P921

Q27851801-43A5C672-A02C-47B6-84EE-DD012195EFA8

Q27851801-8A348239-9A97-4206-81D3-64082D1CF6C6

Q27851801-92E1D72C-3A06-40DA-B97C-EF766FA21476

P932

Q27851801-389D5838-DCF0-48D4-AB8F-39D3CF263C7C

P3181

P356

S0140-6736(12)60398-5

P1433

P1476

Dabrafenib in patients with me ...... phase 1 dose-escalation trial

@en

P2093

Anna C Pavlick

http://www.w3.org/2001/XMLSchema#string

Bo Ma

http://www.w3.org/2001/XMLSchema#string

C Martin Curtis

http://www.w3.org/2001/XMLSchema#string

Daniele Ouellet

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Infante

http://www.w3.org/2001/XMLSchema#string

Kevin B Kim

http://www.w3.org/2001/XMLSchema#string

Michael Millward

http://www.w3.org/2001/XMLSchema#string

Omid Hamid

http://www.w3.org/2001/XMLSchema#string

Peter Lebowitz

http://www.w3.org/2001/XMLSchema#string

P2860

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

P304

1893-1901

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

962951

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(12)60398-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

9829

http://www.w3.org/2001/XMLSchema#string

P478

379

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Brown

Georgina V. Long

Richard F. Kefford

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22608338

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4109288

http://www.w3.org/2001/XMLSchema#string